## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.8% below STRENGTH zone (4.0-10.0%); PEG 1.72 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.41)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. How Is Henry Schein's Stock Performance Compared to Other Healthcare Stocks?**
- Source: FinancialContent | 20251218T075400 | Somewhat-Bullish | Relevance: 100%
- Henry Schein, Inc. (HSIC) is a large-cap healthcare company providing products and services to medical and dental practitioners. Its stock has shown mixed performance, slightly outpacing the Health Care Select Sector SPDR Fund (XLV) over three months but lagging over the year-to-date and 52-week periods. Despite underperforming some rivals like Quest Diagnostics, analysts maintain a "Moderate Buy" rating for HSIC.

**2. How Is Henry Schein's Stock Performance Compared to Other Healthcare Stocks?**
- Source: inkl | 20251218T130759 | Somewhat-Bullish | Relevance: 100%
- Henry Schein, Inc. (HSIC) is a global healthcare product and services provider with a market cap of $9 billion, positioning it as a large-cap stock. While HSIC has seen recent stock gains, slightly outpacing the Health Care Select Sector SPDR Fund (XLV) over three months, its year-to-date and 52-week performance lags XLV and competitor Quest Diagnostics (DGX). Despite this, analysts maintain a "Moderate Buy" rating with a modest price target premium.

**3. Squarepoint Ops LLC Boosts Holdings in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251217T110831 | Somewhat-Bullish | Relevance: 100%
- Squarepoint Ops LLC significantly increased its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 724.4% in the second quarter, now owning 46,841 shares valued at $3.42 million. Other institutional investors like Ameriprise Financial Inc. and Norges Bank also made substantial changes to their HSIC holdings. Analyst ratings for Henry Schein are mixed, with an average "Hold" rating and a price target of $76.92.

**4. Highlights and insights from Henry Scheinâ€™s new report predicting 2026 dental data**
- Source: Dental Economics | 20251218T180419 | Somewhat-Bullish | Relevance: 99%
- Henry Schein One's 2026 Outlook Trends Report highlights crucial themes for the upcoming year in dentistry, focusing on communication clarity, the role of AI in workflows, and patient affordability. The report suggests that issues like low treatment acceptance stem from communication gaps and cost concerns, while technology, especially AI, can enhance patient experiences and address staffing shortages. Ultimately, practices that prioritize clear communication, leverage AI wisely, and offer flexible payment solutions will be better positioned for success in 2026.

**5. DentScribe Joins Henry Schein One API Exchange as an Authorized Integration Vendor**
- Source: Yahoo Finance Singapore | 20251218T064841 | Somewhat-Bullish | Relevance: 93%
- DentScribe.ai has become an authorized integration vendor with the Henry Schein One API Exchange, enabling seamless integration with Dentrix. This partnership allows dental practices to automate SOAP notes, enhance clinical workflows, and improve revenue outcomes through features like AI-Generated SOAP Notes, DentScribe CoPilot, and a Guided Production System. The collaboration aims to provide dental practices with intuitive, secure, and functional technology to elevate patient care and operational efficiency.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.72 elevated, pricing in significant growth expectations. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.4B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 6.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.72 |
| Forward P/E | 14.6 |
| Current P/E | 15.8 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.2% to 2.8% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.2pp (needs >4.0% for momentum thesis). MRS_5 (-0.8%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.2% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: +STH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.84% (CS: 76) | Neutral |
| RSI_14 | 66.8 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 1.032x | Above |
| vs SMA50 | 1.102x | Above |
| vs SMA200 | 1.115x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $77.35
- **Stop Loss:** $74.41 (3.8% risk)
- **Target:** $80.29 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 408
- **Position Value:** $31,558.80
- **Portfolio %:** 31.56%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*